Table 2. Details of the classification of the selected 27 trials.
Author | Year | Cancer type | Disease status | Specific hypothesis | Multiple domains (more than one scale or domain included in the analysis) | QOL questionnaire | If yes, was statistical correction used (multiple domains were independently tested)? | Repeated assessments (more than one follow-up assessment included in the analysis) | If yes, was a statistical technique used that allowed the inclusion of repeated assessment points, or was a statistical correction used (if repeated assessments were independently tested)? | Reporting of descriptive data | Primary statistical technique | Not reported or unclear | (Generalized) linear mixed models, including pattern mixture models | Wilcoxon rank-sums test or between-subjects t-test | ANOVA or linear regression | Time to event | Repeated measures ANOVA | Proportion of patients or responder analysis | Others | Reporting of clinical relevance | Change of X points (from baseline) | X points difference (between arms) | Change of X points from baseline and X points differences (between arms) | Assessed baseline | Compared baseline scores between treatment arms | Included baseline as a covariate | Intention-to-treat population | Baseline compliance rates for each treatment arm | Follow-up compliance rates for each treatment arm | Strategy to handle missing data |
Hagiwara, Y | 2018 | Pancreas | Curative | Yes | No | EQ-5D-3L | Yes | Yes | Yes | Yes | No | Yes | No | No | No | No | No | No | Yes | Yes | No | No | Yes | Yes | Yes | No | Yes | Yes | Yes | |
Kawahara, T | 2018 | Breast | Unresectable | No | Yes | EORTC QLQ-C30, Patient Neurotoxicity Questionnaire | No | Yes | Yes | Yes | Yes | No | No | No | No | Yes | No | No | No | Yes | Yes | No | No | Yes | No | No | No | No | Yes | Yes |
Ohashi et, Y | 2018 | Breast | Curative | No | Yes | QOL-ACD, QOL-ACD-B, FACT-ES | No | Yes | Yes | Yes | Yes | No | Yes | No | No | No | No | No | No | No | No | No | No | Yes | Yes | Yes | Yes | No | No | Yes |
Yamamoto, D | 2017 | Breast | Unresectable | No | Yes | EORTC-QLQ-C30 | No | Yes | No | No | No | Yes | No | No | No | No | No | No | No | No | No | No | No | Yes | No | No | No | Yes | Yes | No |
Shiroiwa, T | 2017 | Breast | Unresectable | No | No | EQ-5D | Yes | Yes | Yes | Yes | No | Yes | No | No | No | No | No | No | Yes | Yes | No | No | Yes | Yes | Yes | No | Yes | Yes | Yes | |
Yoshino, S | 2016 | Gastric | Unresectable | No | No | FACT-Biological Response Modifier | Yes | No | No | No | Yes | No | No | No | No | No | No | No | No | No | No | No | Yes | No | No | No | Yes | No | No | |
Yamazaki, K | 2016 | Colorectal | Unresectable | No | Yes | FACT-C, FACT/GOG-Ntx | Not reported or unclear | Yes | Yes | No | Yes | No | No | No | No | No | Yes | No | No | No | No | No | No | Yes | No | No | Not reported or unclear | No | No | Yes |
Nakamura, M | 2016 | Gastric | Curative | Yes | Yes | FACT-Ga, FACT-G | Not reported or unclear | Yes | No | Yes | No | Yes | No | No | No | No | No | No | No | Yes | No | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes |
Yokomizo, A | 2016 | Bladder | Curative | Not reported or unclear | Yes | EORTC QLQ-C30 | Not reported or unclear | No | Yes | Yes | No | No | Yes | No | No | No | No | No | No | No | No | No | Yes | No | No | No | Yes | Yes | No | |
Ito, Y | 2016 | Gastric | Curative | Yes | Yes | EORTC-QLQ-C30, STO22 | Not reported or unclear | Yes | No | No | Yes | No | No | Yes | No | No | No | No | No | Yes | No | Yes | No | Yes | No | No | No | Yes | Yes | Yes |
Kubota, K | 2015 | NSCLC | Unresectable | Not reported or unclear | Yes | EORTC-QLQ-C30, QLQ-LC13 | Not reported or unclear | Yes | Yes | No | Yes | No | No | No | No | No | Yes | No | No | No | No | No | No | Yes | No | Yes | Not reported or unclear | No | Yes | No |
Masuda, K | 2015 | Rectal | Curative | Not reported or unclear | No | Fecal Incontinence Quality of Life | Yes | No | Yes | Yes | No | No | Yes | No | No | No | No | No | No | No | No | No | Not reported or unclear | No | No | No | No | |||
Abe, T | 2015 | NSCLC | Unresectable | Not reported or unclear | No | FACT-L | Yes | Yes | No | Yes | No | No | No | No | No | No | Yes | No | No | No | No | No | Yes | No | Yes | No | Yes | Yes | Yes | |
Matsuyama, H | 2015 | Prostate | Curative | No | Yes | Expanded Prostate Cancer Index Composite | Not reported or unclear | Yes | Not reported or unclear | No | No | Yes | No | No | No | No | No | No | No | No | No | No | No | Yes | Yes | No | No | No | No | No |
Tsukada, H | 2014 | NSCLC | Unresectable | Not reported or unclear | No | FACT-L | No | Yes | Yes | No | No | No | Yes | No | No | No | No | No | No | No | No | Yes | No | Yes | Yes | Yes | Yes | No | ||
Sekine, I | 2013 | SCLC | Unresectable | Not reported or unclear | Yes | FACT-L, EQ-5D | Not reported or unclear | Yes | Yes | No | Yes | No | No | No | Yes | No | No | No | No | No | No | No | No | Yes | No | Yes | No | Yes | Yes | No |
Ueno, H | 2013 | Pancreas | Unresectable | No | No | EQ-5D | Yes | Yes | No | Yes | No | No | No | No | No | No | No | Yes | No | No | No | No | Yes | No | No | Not reported or unclear | No | No | Yes | |
Shimozuma, K | 2012 | Breast | Curative | Yes | Yes | Patient Neurotoxicity Questionnaire, FACT-G, FACT-Neuro-toxicity | Not reported or unclear | Yes | Yes | Yes | Yes | No | No | Yes | No | No | No | No | No | No | No | No | No | Yes | No | Yes | No | Yes | Yes | Yes |
Oizumi, S | 2012 | NSCLC | Unresectable | Not reported or unclear | No | Care Notebook | Yes | Yes | Yes | Yes | No | No | No | No | Yes | No | No | No | Yes | Yes | No | No | Yes | Yes | No | No | Yes | Yes | No | |
Takei, H | 2012 | Breast | Curative | Not reported or unclear | Yes | FACT-B, FACT-ES, CES-D | Not reported or unclear | Yes | Yes | No | Yes | No | Yes | No | No | No | No | No | No | No | No | No | No | Yes | No | Yes | No | Yes | Yes | Yes |
Takiguchi, S | 2012 | Gastric | Curative | Not reported or unclear | Yes | EORTC-QLQ-C30, DAUGS 20 | Not reported or unclear | No | Yes | Yes | No | No | Yes | No | No | No | No | No | No | No | No | No | No | No | No | Yes | Yes | |||
Ishigami, S | 2011 | Gastric | Curative | No | No | Original | Yes | No | Yes | Yes | No | No | Yes | No | No | No | No | No | No | No | No | No | No | No | No | Yes | No | |||
Kawahara, M | 2011 | NSCLC | Unresectable | Not reported or unclear | Yes | FACT-L, FACT-Taxane, FACIT-Sp | Not reported or unclear | Yes | Yes | Yes | Yes | No | Yes | No | No | No | No | No | No | No | No | No | No | Yes | Yes | Yes | No | Yes | Yes | Yes |
Shiroiwa, T | 2011 | Breast | Curative | No | Yes | EQ-5D, FACT-G, FACT-B, FACT-Taxane | Not reported or unclear | Yes | Yes | Yes | Yes | No | Yes | No | No | No | No | No | No | No | No | No | No | Yes | No | Yes | Yes | No | Yes | Yes |
Ohsumi, S | 2011 | Breast | Curative | Not reported or unclear | Yes | FACT-B, FACT-ES, CES-D | Not reported or unclear | Yes | Yes | Yes | Yes | No | No | No | No | No | No | No | Yes | No | No | No | No | Yes | Yes | Yes | No | Yes | Yes | Yes |
Koga, H | 2010 | Bladder | Curative | Not reported or unclear | Yes | EORTC-QLQ-C30 | Not reported or unclear | Yes | No | Yes | Yes | No | No | No | No | No | No | No | Yes | No | No | No | No | Yes | No | No | Not reported or unclear | No | No | No |
Takeda, K | 2010 | NSCLC | Unresectable | Not reported or unclear | No | FACT-L | Yes | Yes | Yes | Yes | No | Yes | No | No | No | No | No | No | No | No | No | No | Yes | No | Not reported or unclear | Yes | Yes | Yes | Yes |